Abstract:RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biologic activity away from their natural equivalents. Novel technologies in development today seek to use intact cells to yield true biologic RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiologic and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA-approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran) as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biologic RNAi agents for research and development. SIGNIFICANCE STATEMENT In our review, we summarize the major concepts of RNA interference (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of US Food and Drug Administration-approved RNAi medications and those siRNAs and miRNA-based therapeutics that entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.

Therapeutic Potential of Plant-Derived Amirnas: Challenges and Strategies

RNA-based Therapeutics: an Overview and Prospectus

MicroRNAs in Medicinal Plants

A Timely Review of Cross-Kingdom Regulation of Plant-Derived MicroRNAs

Therapeutic Potentials of Gene Silencing by RNA Interference: Principles, Challenges, and New Strategies.

Progress and challenges of plant-derived nucleic acids as therapeutics in macrophage-mediated RNA therapy

Small Non-coding RNA in Plants: From Basic Science to Innovative Applications

RNA Interference and Its Application to Metabolic Engineering in Medicinal Plants

Plant Derived Edible Nanoparticles As A New Therapeutic Approach Against Diseases

A New Frontier in Phytotherapy: Harnessing the Therapeutic Power of Medicinal Herb-derived miRNAs

Rna Interference: A Potent Tool for Gene-Specific Therapeutics

Artificial miRNAs are potential gene therapy tools, especially for incurable monogenic disorders

Small Molecules Modulating Biogenesis or Processing of microRNAs with Therapeutic Potentials

miRNA, phytometabolites and disease: Connecting the dots

Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application

MicroRNA therapeutic delivery strategies: A review

Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry

A new approach for therapeutic use by RNA interference in the brain

MicroRNA-based Therapeutic Technologies

Research progress of the methods and atrategies of introducing small interference RNA into mammals

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies